Pharmaceutical Technology
JULY 15, 2022
Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.
pharmaphorum
JUNE 2, 2022
Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ This is based on the relative success orphan drugs have achieved, in terms of the number of approvals and the sales figures achieved for this area. Reaching a compromise.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 22, 2022
Musk’s arrival at the social platform has raised questions for users, which includes pharma companies who use Twitter for marketing and patients who utilise it to engage with their medical communities. The post Elon Musk, pharma, and the future of Twitter appeared first on.
pharmaphorum
AUGUST 11, 2020
In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. This will also mean the industry needs to think about how HCPs will want to interact with pharma companies. “If
Delveinsight
AUGUST 25, 2021
The combined sales of the Immunology (15%) and Oncology (38%) sectors were more than 50% of the total revenue in 2020. They both made a sale of USD 3.8 The annual sale of Novartis in the year 2020 was USD 48.6 The annual sale of Merck and Company in the year 2020 was USD 47.9 billion), Infectious Disease (USD 0.86
pharmaphorum
JUNE 10, 2021
The fundamental misconception among the public, the media and even some lawmakers is that higher drug list prices are the result of drug manufacturers being in a monopolistic position to endlessly raise prices on critical drugs like insulin and then rake in big profits. What’s Next: How Should Pharma Companies Respond?
XTalks
SEPTEMBER 11, 2023
billion Insulin Aspart Maker: Novo Nordisk Treatment for: Diabetes Medicare Spend: $2.6 Astellas Pharma was also part of the litigating pharma companies but withdrew its lawsuit last Thursday, as it managed to evade CMS’ initial negotiation list. However, Pfizer and BMS listed the drug’s 2022 US sales to be $7.8
Expert insights. Personalized for you.
328 
Let's personalize your content